Meeting
Abstract Number: 317
Hospital Medicine 2020, Virtual Competition
Background: Myelofibrosis is a chronic myeloproliferative neoplasm characterized by progressive bone marrow fibrosis and extramedullary hematopoiesis leading to splenomegaly. Progressive splenomegaly is common in advanced myelofibrosis, and spleen volume is a predictor of survival. The oral selective small-molecule JAK 1/2 inhibitor ruxolitinib is used for symptomatic management of intermediate-2 and high-risk myelofibrosis, and leads to […]
Abstract Number: 547
Hospital Medicine 2018; April 8-11; Orlando, Fla.
Case Presentation: A 78 y/o M with PMH of papillary thyroid CA, BPH, and primary myelofibrosis of the bone marrow (has JAK2 mutation, leukocytosis and thrombocytosis, has not received therapy to date) presented with 8 day history of early satiety, fatigue, and new increasing ascites. An inItial diagnostic paracentesis showed SAAG = 1.1, total protein […]
Abstract Number: 689
Hospital Medicine 2020, Virtual Competition
Case Presentation: A 76-year-old Chinese woman with history of cryptogenic cirrhosis (MELD-Na 25) presented to our hospital with 1 week of worsening jaundice, abdominal distension, and right upper quadrant pain. Cirrhosis was diagnosed by imaging on admission 2 months previously and presumed to be secondary to Hepatitis C infection due to antibody positivity. CT of […]